Comparison of different approaches to predict metabolic drug–drug interactions

Xenobiotica

Volumn 37, Issue 42288, 2007, Pages 1257-1294

  Einolf, H J ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

cytochrome P450; Drug drug interactions; inhibition; prediction of drug drug interactions

Indexed keywords

CIMETIDINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 INHIBITOR; DESIPRAMINE; DILTIAZEM; DIPHENHYDRAMINE; ENOXACIN; ERYTHROMYCIN; FLUCONAZOLE; FLUINDOSTATIN; FLUOXETINE; FLUVOXAMINE; ITRACONAZOLE; KETOCONAZOLE; OMEPRAZOLE; PAROXETINE; QUINIDINE; RITONAVIR; SULFAPHENAZOLE; TERBINAFINE; VERAPAMIL;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; AUTOMATION; CLINICAL EVALUATION; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); DRUG INTERACTION; DYNAMICS; INTESTINE; METABOLISM; MODEL; NONHUMAN; PHYSIOLOGY; POPULATION RESEARCH; PREDICTION; RAT; SIMULATION; SIMULATOR; TIME;

COMPUTER SIMULATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; MODELS, BIOLOGICAL; XENOBIOTICS;

EID: 35648968125     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498250701620700     Document Type: Article

References (146)

1. Abdul MR, Wright CE, Gregory A, Rostami-Hodjegan A, Meller ST, Kelm GR, Lennard MS, Tucker GT, Morice AH. The antitussive effect of dextromethorphan in relation to CYP2D6 activity. British Journal of Clinical Pharmacology 1999; 48 (3) 382 – 387
2. Abelo A, Andersson TB, Antonsson M, Naudot AK, Skanberg I, Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metabolism and Disposition 2000; 28 (8) 966 – 972
3. Ahonen J, Olkkola KT, Neuvonen PJ. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. European Journal of Clinical Pharmacology 1997; 51 (5) 415 – 419
4. Albert KS, Hallmark MR, Sakmar E, Weidler DJ, Wagner JG. Pharmacokinetics of diphenhydramine in man. Journal of Pharmacokinetics and Biopharmacology 1975; 3 (3) 159 – 170
5. Alderman J, Preskorn SH, Greenblatt DJ, Harrison W, Penenberg D, Allison J, Chung M. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. Journal of Clinical Psychopharmacology 1997; 17 (4) 284 – 291
6. Appel S, Rufenacht T, Kalafsky G, Tetzloff W, Kallay Z, Hitzenberger G, Kutz K. Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus. American Journal of Cardiology 1995; 76 (2) 29A – 32A
7. Austin RP, Barton P, Cockroft SL, Wenlock MC, Riley RJ. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metabolism and Disposition 2002; 30 (12) 1497 – 1503
8. Ayesh R, Dawling S, Hayler A, Oates NS, Cholerton S, Widdop B, Idle JR, Smith RL. Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers. Chirality 1991; 3 (1) 14 – 18
9. Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ. The area under the plasma concentration–time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. European Journal of Clinical Pharmacology 1998; 54 (1) 53 – 58
10. Backman JT, Olkkola KT, Aranko K, Himberg JJ, Neuvonen PJ. Dose of midazolam should be reduced during diltiazem and verapamil treatments. British Journal of Clinical Pharmacology 1994; 37 (3) 221 – 225
11. Balfour JA, Faulds D. Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992; 43 (2) 259 – 284
12. Ball SE, Ahern D, Scatina J, Kao J. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. British Journal of Clinical Pharmacology 1997; 43 (6) 619 – 626
13. Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JGC. Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin. Acta Psychiatrica Scandinavica 1989; 80 (Suppl. 350) 102 – 106
14. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clinical Pharmacology and Therapy 1992; 51 (3) 239 – 248
15. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, et al. The conduct of in vitro and in vivo drug–drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metabolism and Disposition 2003; 31 (7) 815 – 832
16. Black DJ, Kunze KL, Wienkers LC, Gidal BE, Seaton TL, McDonnell ND, Evans JS, Bauwens JE, Trager WF. Warfarin-fluconazole. II. A metabolically based drug interaction: In vivo studies. Drug Metabolism and Disposition 1996; 24 (4) 422 – 428
17. Blanchard N, Richert L, Coassolo P, Lave T. Qualitative and quantitative assessment of drug–drug interaction potential in man, based on Ki, IC50 and inhibitor concentration. Current Drug Metabolism 2004; 5 (2) 147 – 156
18. Blyden GT, Greenblatt DJ, Scavone JM, Shader RI. Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration. Journal of Clinical Pharmacology 1986; 26 (7) 529 – 533
19. Bondolfi G, Chautems C, Rochat B, Bertschy G, Baumann P. Non-response to citalopram in depressive patients: Pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology (Berlin) 1996; 128 (4) 421 – 425
20. Bottiger Y, Tybring G, Gotharson E, Bertilsson L. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clinical Pharmacology and Therapy 1997; 62 (4) 384 – 391
21. Brannan MD, Reidenberg P, Radwanski E, Shneyer L, Lin CC, Cayen MN, Affrime MB. Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations. Clinical Pharmacology and Therapy 1995; 58 (3) 269 – 278
22. Brown HS, Chadwick A, Houston JB. Use of isolated hepatocyte preparations for P450 inhibition studies: Comparison with microsomes for Ki determination. Drug Metabolism and Disposition. 2007, (in press)
23. Brown HS, Galetin A, Hallifax D, Houston JB. Prediction of in vivo drug–drug interactions from in vitro data: factors affecting prototypic drug–drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clinical Pharmacokinetics 2006; 45 (10) 1035 – 1050
24. Brown HS, Ito K, Galetin A, Houston JB. Prediction of in vivo drug–drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. British Journal of Clinical Pharmacology 2005; 60 (5) 508 – 518
25. Calvo G, Garcia-Gea C, Luque A, Morte A, Dal Re R, Barbanoj M. Lack of pharmacologic interaction between paroxetine and alprazolam at steady state in healthy volunteers. Journal of Clinical Psychopharmacology 2004; 24 (3) 268 – 276
26. Cate EW, Rogers JF, Powell JR. Inhibition of tolbutamide elimination by cimetidine but not ranitidine. Journal of Clinical Pharmacology 1986; 26 (5) 372 – 377
27. Chang WH, Augustin B, Lane HY, ZumBrunnen T, Liu HC, Kazmi Y, Jann MW. In-vitro and in-vivo evaluation of the drug–drug interaction between fluvoxamine and clozapine. Psychopharmacology (Berlin) 1999; 145 (1) 91 – 98
28. Chellingsworth MC, Laugher S, Akhlaghi S, Jack DB, Kendall MJ. The effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of metoprolol. Aliment Pharmacology and Therapy 1988; 2 (6) 521 – 527
29. Christensen M, Tybring G, Mihara K, Yasui-Furokori N, Carrillo JA, Ramos SI, Andersson K, Dahl ML, Bertilsson L. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clinical Pharmacology and Therapy 2002; 71 (3) 141 – 152
30. Collins C, Levy R, Ragueneau-Majlessi I, Hachad H. Prediction of maximum exposure in poor metabolizers following inhibition of nonpolymorphic pathways. Current Drug Metabolism 2006; 7 (3) 295 – 299
31. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clinical Pharmacokinetics 1988; 14 (1) 13 – 34
32. Debruyne D, Ryckelynck JP. Clinical pharmacokinetics of fluconazole. Clinical Pharmacokinetics 1993; 24 (1) 10 – 27
33. DeVane CL, Donovan JL, Liston HL, Markowitz JS, Cheng KT, Risch SC, Willard L. Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. Journal of Clinical Psychopharmacology 2004; 24 (1) 4 – 10
34. DeVane CL, Savett M, Jusko WJ. Desipramine and 2-hydroxy-desipramine pharmacokinetics in normal volunteers. European Journal of Clinical Pharmacology 1981; 19 (1) 61 – 64
35. Dixit AA, Rao YM. Pharmacokinetic interaction between diltiazem and tolbutamide. Drug Metabolism Drug Interactions 1999; 15 (4) 269 – 277
36. Eap CB, Buclin T, Cucchia G, Zullino D, Hustert E, Bleiber G, Golay KP, Aubert AC, Baumann P, Telenti A, et al. Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. European. Journal of Clinical Pharmacology 2004; 60 (4) 237 – 246
37. Ernest CS, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. Journal of Pharmacology Experimental Therapy 2005; 312 (2) 583 – 591
38. Fabrazzo M, La Pia S, Monteleone P, Mennella R, Esposito G, Pinto A, Maj M. Fluvoxamine increases plasma and urinary levels of clozapine and its major metabolites in a time- and dose-dependent manner. Journal of Clinical Psychopharmacology 2000; 20 (6) 708 – 710
39. Fischer V, Johanson L, Heitz F, Tullman R, Graham E, Baldeck JP, Robinson WT. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metabolism and Disposition 1999; 27 (3) 410 – 416
40. Fuhr U, Woodcock BG, Siewert M. Verapamil and drug metabolism by the cytochrome P450 isoform CYP1A2. European Journal of Clinical Pharmacology 1992; 42 (4) 463 – 464
41. Galetin A, Burt H, Gibbons L, Houston JB. Prediction of time-dependent CYP3A4 drug–drug interactions: Impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metabolism and Disposition 2006; 34 (1) 166 – 175
42. Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clinical Pharmacology and Therapy 1992; 52 (5) 479 – 486
43. Greenblatt DJ, Von Moltke LL, Harmatz JS, Counihan M, Graf JA, Durol AL, Mertzanis P, Duan SX, Wright CE, Shader RI. Inhibition of triazolam clearance by macrolide antimicrobial agents: In vitro correlates and dynamic consequences. Clinical Pharmacology and Therapy 1998a; 64 (3) 278 – 285
44. Greenblatt DJ, Von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, Mertzanis P, Hoffman JL, Shader RI. Alprazolam–ritonavir interaction: Implications for product labeling. Clinical Pharmacology and Therapy 2000a; 67 (4) 335 – 341
45. Greenblatt DJ, Von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, Mertzanis P, Hoffman JL, Shader RI. Differential impairment of triazolam and zolpidem clearance by ritonavir. Journal of Acquired Immune Deficiency Syndrome 2000b; 24 (2) 129 – 136
46. Greenblatt DJ, Wright CE, Von Moltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, Corbett K, Counihan M, Tobias S, Shader RI. Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences. Clinical Pharmacology and Therapy 1998b; 64 (3) 237 – 247
47. Guerret M, Francheteau P, Hubert M. Evaluation of effects of terbinafine on single oral dose pharmacokinetics and anticoagulant actions of warfarin in healthy volunteers. Pharmacotherapy 1997; 17 (4) 767 – 773
48. Hall J, Naranjo CA, Sproule BA, Herrmann N. Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine. Journal of Clinical Psychopharmacology 2003; 23 (4) 349 – 357
49. Hallifax D, Houston JB. Uptake and intracellular binding of lipophilic amine drugs by isolated rat hepatocytes and implications for prediction of in vivo metabolic clearance. Drug Metabolism and Disposition 2006; 34 (11) 1829 – 1836
50. Hallifax D, Houston JB. Saturable uptake of lipophilic amine drugs into isolated hepatocytes: mechanisms and consequences or quantitative clearance prediction. Drug Metabolism and Disposition 2007; 35 (8) 1325 – 1332
51. Hamelin BA, Bouayad A, Drolet B, Gravel A, Turgeon J. In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. Drug Metabolism and Disposition 1998; 26 (6) 536 – 539
52. Hamelin BA, Bouayad A, Methot J, Jobin J, Desgagnes P, Poirier P, Allaire J, Dumesnil J, Turgeon J. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clinical Pharmacology and Therapy 2000; 67 (5) 466 – 477
53. Hoglund P, Nilsson LG. Pharmacokinetics of diltiazem and its metabolites after repeated multiple-dose treatments in healthy volunteers. Therapy and Drug Monitoring 1989; 11 (5) 543 – 550
54. Howgate EM, Rowland YK, Proctor NJ, Tucker GT, Rostami-Hodjegan A. Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability. Xenobiotica 2006; 36 (6) 473 – 497
55. Huang YC, Colaizzi JL, Bierman RH, Woestenborghs R, Heykants J. Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrobial Agents and Chemotherapy 1986; 30 (2) 206 – 210
56. Ito K, Brown HS, Houston JB. Database analyses for the prediction of in vivo drug–drug interactions from in vitro data. British Journal of Clinical Pharmacology 2004; 57 (4) 473 – 486
57. Ito K, Hallifax D, Obach RS, Houston JB. Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug–drug interactions: CYP2D6 paradigm. Drug Metabolism and Disposition 2005; 33 (6) 837 – 844
58. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug–drug interactions: metabolic interaction in the liver. Pharmacology Reviews 1998; 50 (3) 387 – 412
59. Jaehde U, Sorgel F, Naber KG, Zurcher J, Schunack W. Distribution kinetics of enoxacin and its metabolite oxoenoxacin in excretory fluids of healthy volunteers. Antimicrobial Agents and Chemotherapy 1995; 39 (9) 2092 – 2097
60. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clinical Pharmacokinetics 2006; 45 (9) 931 – 956
61. Kalgutkar AS, Obach RS, Maurer TS. Mechanism-based inactivation of cytochrome P450 enzymes: Chemical mechanisms, structure–activity relationships and relationship to clinical drug–drug interactions and idiosyncratic adverse drug reactions. Current Drug Metabolism 2007; 8 (5) 407 – 447
62. Kanamitsu S, Ito K, Sugiyama Y. Quantitative prediction of in vivo drug–drug interactions from in vitro data based on physiological pharmacokinetics: Use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharmacology Research 2000; 17 (3) 336 – 343
63. Kang BC, Yang CQ, Cho HK, Suh OK, Shin WG. Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. Biopharmacology and Drug Disposition 2002; 23 (2) 77 – 81
64. Kantola T, Backman JT, Niemi M, Kivisto KT, Neuvonen PJ. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. European Journal of Clinical Pharmacology 2000; 56 (3) 225 – 229
65. Karam WG, Goldstein JA, Lasker JM, Ghanayem BI. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metabolism and Disposition 1996; 24 (10) 1081 – 1087
66. Kharasch ED, Walker A, Hoffer C, Sheffels P. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. Journal of Clinical Pharmacology 2005; 45 (10) 1187 – 1197
67. Kirch W, Spahn H, Kohler H, Ohnhaus EE, Mutschler E. Interaction of metoprolol, propranolol and atenolol with concurrent administration of cimetidine. Klinische Wochenschrift 1982; 60 (22) 1401 – 1407
68. Konishi H, Morita K, Yamaji A. Effect of fluconazole on theophylline disposition in humans. European Journal of Clinical Pharmacology 1994; 46 (4) 309 – 312
69. Kosoglou T, Salfi M, Lim JM, Batra VK, Cayen MN, Affrime MB. Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazole or cimetidine. British Journal of Clinical Pharmacology 2000; 50 (6) 581 – 589
70. Kosuge K, Nishimoto M, Kimura M, Umemura K, Nakashima M, Ohashi K. Enhanced effect of triazolam with diltiazem. British Journal of Clinical Pharmacology 1997; 43 (4) 367 – 372
71. Krishnaiah YS, Satyanarayana S, Visweswaram D. Interaction between tolbutamide and ketoconazole in healthy subjects. British Journal of Clinical Pharmacology 1994; 37 (2) 205 – 207
72. Laine K, De Bruyn S, Bjorklund H, Rouru J, Hanninen J, Scheinin H, Anttila M. Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics. European Journal of Clinical Pharmacology 2004; 59 (12) 893 – 898
73. Lam YW, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. Journal of Clinical Pharmacology 2003; 43 (11) 1274 – 1282
74. Lazar JD, Wilner KD. Drug interactions with fluconazole. Reviews in Infectious Diseases 1990; 12 (Suppl. 3) S327 – S333
75. Madani S, Barilla D, Cramer J, Wang Y, Paul C. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. Journal of Clinical Pharmacology 2002; 42 (11) 1211 – 1218
76. Madeira M, Levine M, Chang TK, Mirfazaelian A, Bellward GD. The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6. Drug Metabolism and Disposition 2004; 32 (4) 460 – 467
77. Madsen H, Enggaard TP, Hansen LL, Klitgaard NA, Brosen K. Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. Clinical Pharmacology and Therapy 2001; 69 (1) 41 – 47
78. Mayhew BS, Jones DR, Hall SD. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metabolism and Disposition 2000; 28 (9) 1031 – 1037
79. Mutschler E, Spahn H, Kirch W. The interaction between H2-receptor antagonists and beta-adrenoceptor blockers. British Journal of Clinical Pharmacology 1984; 17 (Suppl. 1) 51S – 57S
80. Nakamura H, Sano H, Yamazaki M, Sugiyama Y. Carrier-mediated active transport of histamine H2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: contribution of type I system. Journal of Pharmacology and Experimental Therapy 1994; 269 (3) 1220 – 1227
81. Naline E, Sanceaume M, Pays M, Advenier C. Application of theophylline metabolite assays to the exploration of liver microsome oxidative function in man. Fundamentals of Clinical Pharmacology 1988; 2 (4) 341 – 351
82. Neal JM, Kunze KL, Levy RH, O’Reilly RA, Trager WF. Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition. Drug Metabolism and Disposition 2003; 31 (8) 1043 – 1048
83. Neuvonen PJ, Varhe A, Olkkola KT. The effect of ingestion time interval on the interaction between itraconazole and triazolam. Clinical Pharmacology and Therapy 1996; 60 (3) 326 – 331
84. Niki Y, Soejima R, Kawane H, Sumi M, Umeki S. New synthetic quinolone antibacterial agents and serum concentration of theophylline. Chest 1987; 92 (4) 663 – 669
85. Obach RS, Walsky RL, Venkatakrishnan K. Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug–drug interactions. Drug Metabolism and Disposition 2006a; 35: 246 – 255
86. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug–drug interactions. Journal of Pharmacology Experimental Therapy 2006b; 316 (1) 336 – 348
87. Ohtawa M, Masuda N, Akasaka I, Nakashima A, Ochiai K, Moriyasu M. Cellular uptake of fluvastatin, an inhibitor of HMG-Coa reductase, by rat cultured hepatocytes and human aortic endothelial cells. British Journal of Clinical Pharmacology 1999; 47: 383 – 389
88. Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesthesia and Analgesia 1996; 82 (3) 511 – 516
89. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clinical Pharmacology and Therapy 1994; 55 (5) 481 – 485
90. Olkkola KT, Isohanni MH, Hamunen K, Neuvonen PJ. The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine. Anesthesia and Analgesia 2005; 100 (5) 1352 – 1356
91. O’Reilly RA. Comparative interaction of cimetidine and ranitidine with racemic warfarin in man. Archives of Internal Medicine 1984; 144 (5) 989 – 991
92. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clinical Pharmacology and Therapy 1993; 53 (4) 401 – 409
93. Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a ‘well-stirred’ model and a ‘parallel tube’ model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. Journal of Pharmacokinetics and Biopharmacology 1977; 5 (6) 625 – 653
94. Poirier JM, Cheymol G. Optimisation of itraconazole therapy using target drug concentrations. Clinical Pharmacokinetics 1998; 35 (6) 461 – 473
95. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. Journal of Clinical Psychopharmacology 1994; 14 (2) 90 – 98
96. Rasmussen BB, Jeppesen U, Gaist D, Brosen K. Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. Therapy and Drug Monitoring 1997; 19 (1) 56 – 62
97. Rodrigues AD, Winchell GA, Dobrinska MR. Use of in vitro drug metabolism data to evaluate metabolic drug–drug interactions in man: The need for quantitative databases. Journal of Clinical Pharmacology 2001; 41 (4) 368 – 373
98. Rostami-Hodjegan A, Tucker G. ‘In silico’ simulations to assess the ‘in vivo’ consequences of ‘in vitro’ metabolic drug–drug interactions. Drug Discovery Today 2004; 1 (4) 441 – 448
99. Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nature Reviews in Drug Discovery 2007; 6 (2) 140 – 148
100. Sallee FR, Pollock BG. Clinical pharmacokinetics of imipramine and desipramine. Clinical Pharmacokinetics 1990; 18 (5) 346 – 364
101. Sax MJ, Randolph WC, Peace KE, Chretien S, Frank WO, Braverman AJ, Gray DR, McCree LC, Wyle F, Jackson BJ, et al. Effect of two cimetidine regimens on prothrombin time and warfarin pharmacokinetics during long-term warfarin therapy. Clinical Pharmacology 1987; 6: 492 – 495
102. Schmider J, Brockmoller J, Arold G, Bauer S, Roots I. Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. Pharmacogenetics 1999; 9 (6) 725 – 734
103. Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clinical Pharmacokinetics 2001; 40 (4) 263 – 281
104. Sharma A, Pibarot P, Pilote S, Dumesnil JG, Arsenault M, Belanger PM, Meibohm B, Hamelin BA. Modulation of metoprolol pharmacokinetics and hemodynamics by diphenhydramine coadministration during exercise testing in healthy premenopausal women. Journal of Pharmacology Experimental Therapy 2005; 313 (3) 1172 – 1181
105. Shiran MR, Proctor NJ, Howgate EM, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. Prediction of metabolic drug clearance in humans: In vitro–in vivo extrapolation versus allometric scaling. Xenobiotica 2006; 36 (7) 567 – 580
106. Sirmans SM, Pieper JA, Lalonde RL, Smith DG, Self TH. Effect of calcium channel blockers on theophylline disposition. Clinical Pharmacology and Therapy 1988; 44 (1) 29 – 34
107. Somogyi A, Gugler R. Clinical pharmacokinetics of cimetidine. Clinical Pharmacokinetics 1983; 8 (6) 463 – 495
108. Somogyi AA, Bochner F. The absorption and disposition of enoxacin in healthy subjects. Journal of Clinical Pharmacology 1988; 28 (8) 707 – 713
109. Spector R, Choudhury AK, Chiang CK, Goldberg MJ, Ghoneim MM. Diphenhydramine in Orientals and Caucasians. Clinical Pharmacology and Therapy 1980; 28 (2) 229 – 234
110. Steiner E, Spina E. Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators. Clinical Pharmacology and Therapy 1987; 42 (3) 278 – 282
111. Tateishi T, Nakashima H, Shitou T, Kumagai Y, Ohashi K, Hosoda S, Ebihara A. Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol. European Journal of Clinical Pharmacology 1989; 36 (1) 67 – 70
112. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and cimetidine: Assessment of pharmacokinetic changes following single and multiple doses. British Journal of Clinical Pharmacology 1998; 46 (Suppl. 1) 25 – 29
113. Trepanier EF, Nafziger AN, Amsden GW. Effect of terbinafine on theophylline pharmacokinetics in healthy volunteers. Antimicrobial Agents and Chemotherapy 1998; 42 (3) 695 – 697
114. Tse FL, Jaffe JM, Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. Journal of Clinical Pharmacology 1992; 32 (7) 630 – 638
115. Tse FL, Nickerson DF, Yardley WS. Binding of fluvastatin to blood cells and plasma proteins. Journal of Pharmaceutical Sciences 1993; 82 (9) 942 – 947
116. Tsunoda SM, Velez RL, Von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clinical Pharmacology and Therapy 1999; 66 (5) 461 – 471
117. Tucker GT. The rational selection of drug interaction studies: Implications of recent advances in drug metabolism. International Journal of Clinical Pharmacology, Therapy and Toxicology 1992; 30 (11) 550 – 553
118. Tucker GT, Houston JB, Huang SM. Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential — towards a consensus. British Journal of Clinical Pharmacology 2001; 52 (1) 107 – 117
119. Tucker GT, Rostami-Hodjegan A, Jackson PR. Determination of drug-metabolizing enzyme activity in vivo: Pharmacokinetic and statistical issues. Xenobiotica 1998; 28 (12) 1255 – 1273
120. Turgeon J, Fiset C, Giguere R, Gilbert M, Moerike K, Rouleau JR, Kroemer HK, Eichelbaum M, Grech-Belanger O, Belanger PM. Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. Journal of Pharmacology and Experimental Therapy 1991; 259 (2) 789 – 798
121. US Food and Drug Administration (FDA). Draft guidance for industry: drug interaction studies — study design, data analysis, and implications for dosing and labeling 2006, September 2006
122. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clinical Pharmacology and Therapy 1994; 56 (6 Pt 1) 601 – 607
123. Varhe A, Olkkola KT, Neuvonen PJ. Diltiazem enhances the effects of triazolam by inhibiting its metabolism. Clinical Pharmacology and Therapy 1996a; 59 (4) 369 – 375
124. Varhe A, Olkkola KT, Neuvonen PJ. Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. British Journal of Clinical Pharmacology 1996b; 42 (4) 465 – 470
125. Varhe A, Olkkola KT, Neuvonen PJ. Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. British Journal of Clinical Pharmacology 1996c; 41 (4) 319 – 323
126. Venkatakrishnan K, Obach RS. In vitro–in vivo extrapolation of CYP2D6 inactivation by paroxetine: Prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metabolism and Disposition 2005; 33 (6) 845 – 852
127. Veronese ME, Miners JO, Randles D, Gregov D, Birkett DJ. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clinical Pharmacology and Therapy 1990; 47 (3) 403 – 411
128. Von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, Shader RI. Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. Journal of Pharmacology Experimental Therapy 1996; 276 (2) 370 – 379
129. Vree TB, Beneken Kolmer EW, Hekster YA. High pressure liquid chromatographic analysis and preliminary pharmacokinetics of sulfaphenazole and its N2-glucuronide and N4-acetyl metabolites in plasma and urine of man. Pharmacentisch Weekblad Scientific Edition 1990; 12 (6) 243 – 246
130. Wang CY, Zhang ZJ, Li WB, Zhai YM, Cai ZJ, Weng YZ, Zhu RH, Zhao JP, Zhou HH. The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers. Journal of Clinical Pharmacology 2004a; 44 (7) 785 – 792
131. Wang YH, Jones DR, Hall SD. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metabolism and Disposition 2004b; 32 (2) 259 – 266
132. Wijnands WJ, Vree TB, Van Herwaarden CL. The influence of quinolone derivatives on theophylline clearance. British Journal of Clinical Pharmacology 1986; 22 (6) 677 – 683
133. Wolf R, Eberl R, Dunky A, Mertz N, Chang T, Goulet JR, Latts J. The clinical pharmacokinetics and tolerance of enoxacin in healthy volunteers. Journal of Antimicrobogy and Chemotherapy 1984; 14 (Suppl. C) 63 – 69
134. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharmacology Research 2005; 22 (1) 11 – 23
135. Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. Kinetic values for mechanism-based enzyme inhibition: Assessing the bias introduced by the conventional experimental protocol. European Journal of Pharmacology Science 2005; 26 (3–4) 334 – 340
136. Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition. European Journal of Pharmacology Science 2007; 31 (3–4) 232 – 241
137. Yang JS, Rostami-Hodjegan A, Tucker GT. Prediction of fluconazole interaction with midazolam and triazolam: Incorporating population variability. British Journal of Clinical Pharmacology 2001a; 52: 484P
138. Yang JS, Rostami-Hodjegan A, Tucker GT. Prediction of ketoconazole interaction with midazolam, alprazolam and triazolam: Incorporating population variability. British Journal of Clinical Pharmacology 2001b; 52: 472P – 473P
139. Yang JS, Rostami-Hodjegan A, Tucker GT. Prediction of ritonavir interaction with sildenafil (Viagra): Incorporating population variability. British Journal of Clinical Pharmacology 2001c; 53: 438P – 439P
140. Yao C, Kunze KL, Kharasch ED, Wang Y, Trager WF, Ragueneau I, Levy RH. Fluvoxamine–theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. Clinical Pharmacology and Therapy 2001; 70 (5) 415 – 424
141. Yao C, Kunze KL, Trager WF, Kharasch ED, Levy RH. Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. Drug Metabolism and Disposition 2003; 31 (5) 565 – 571
142. Yao C, Levy RH. Inhibition-based metabolic drug–drug interactions: Predictions from in vitro data. Journal of Pharmacology Science 2002; 91 (9) 1923 – 1935
143. Yasui N, Kondo T, Otani K, Furukori H, Kaneko S, Ohkubo T, Nagasaki T, Sugawara K. Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology (Berlin) 1998; 139 (3) 269 – 273
144. Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Sugawara K, Chiba K, Ishizaki T. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: In vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clinical Pharmacology and Therapy 1996; 59 (5) 514 – 519
145. Yasui-Furukori N, Takahata T, Nakagami T, Yoshiya G, Inoue Y, Kaneko S, Tateishi T. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. British Journal of Clinical Pharmacology 2004; 57 (4) 487 – 494
146. Zimmermann T, Yeates RA, Laufen H, Scharpf F, Leitold M, Wildfeuer A. Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. Arzneimittelforschung 1996; 46 (2) 213 – 237